早期三阴性乳腺癌辅助EC-T联合卡铂的III期随机试验
RJBC 1501是一项III期随机试验,纳入786例早期三阴性乳腺癌患者,随机接受EC-T或EC-TCb辅助化疗。中位随访4.52年,EC-TCb组显著改善DFS(HR 0.66)、DDFS(HR 0.61)和OS(HR 0.39)。两组3-4级不良事件发生率分别为49.9%和38.7%,主要为血液学毒性。
要点
- EC-TCb较EC-T显著改善早期TNBC的DFS、DDFS和OS。
- EC-TCb组3-4级不良事件更常见,主要为中性粒细胞减少和血小板减少。
- 该方案未发现新的安全性信号。
核心结论
- 在早期三阴性乳腺癌辅助化疗中,EC-T基础上加用卡铂显著改善无病生存、无远处转移生存和总生存。
- 尽管血液学毒性增加,但未观察到新的安全性信号。
研究设计与样本
- III期随机对照试验,纳入786例接受根治性手术的早期三阴性乳腺癌患者(淋巴结阳性或阴性但肿瘤≥1.0 cm)。
- 按淋巴结状态分层,1:1随机分配至EC-T组(n=391)或EC-TCb组(n=395)。
- 主要终点为无病生存,次要终点包括无远处转移生存、总生存和安全性。
主要发现
- 中位随访4.52年(IQR 2.83-6.06),EC-T组和EC-TCb组分别报告62例和41例事件。
- EC-TCb组3-4级不良事件发生率49.9%,EC-T组38.7%,主要为中性粒细胞减少(47.0% vs 37.8%)和血小板减少(4.5% vs 0%)。
关键数值与推荐
- 3-4级中性粒细胞减少发生率EC-TCb组47.0%,EC-T组37.8%。
- 3-4级血小板减少发生率EC-TCb组4.5%,EC-T组0%。
临床怎么用
- 对于早期三阴性乳腺癌患者,可考虑在EC-T辅助化疗基础上加用卡铂以改善生存。
- 需密切监测血液学毒性,尤其是中性粒细胞减少和血小板减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of adjuvant epirubicin plus cyclophosphamide followed by taxanes (EC-T) versus EC-T plus carboplatin (EC-TCb) in patients with early-stage triple-negative breast cancer (TNBC). PATIENTS AND METHODS: In this phase III trial, patients with TNBC with node-positive or node-negative (tumor size ≥1.0 cm) disease who received definitive surgery, were stratified by lymph node status and randomly assigned in a 1:1 ratio to receive four cycles of EC followed by four cycles T with or without carboplatin adjuvant chemotherapy. The primary end point was disease-free survival (DFS). Secondary end points included distant DFS (DDFS), overall survival (OS), and safety. This study had 80% power to detect a DFS hazard ratio (HR) of 0.64, with a two-sided type I error of 0.05. RESULTS: A total of 786 patients were randomly assigned to receive EC-T (n = 391) or EC-TCb (n = 395) between March 2016 and March 2023. With a median follow-up of 4.52 (IQR, 2.83-6.06) years, 62 and 41 events were reported in the EC-T and EC-TCb arm, respectively. Adding carboplatin significantly improved DFS (HR, 0.66; [95% CI, 0.44 to 0.97]; P = .034), DDFS (HR, 0.61 [95% CI, 0.38 to 0.98]; P = .040), and OS (HR, 0.39 [95% CI, 0.16 to 0.94]; P = .029). Grade 3 to 4 adverse events were more frequent among the EC-TCb arm (49.9%) than the EC-T arm (38.7%), primarily driven by higher incidence of neutropenia (47.0% v 37.8%) and thrombocytopenia (4.5% v 0%). Other grade 3 to 4 toxicities were comparable. CONCLUSION: Adding carboplatin to adjuvant EC-T chemotherapy significantly improves DFS, DDFS, and OS in patients with early-stage TNBC. Although increased hematologic toxicity was observed, no new safety signals emerged.
引用
- Chen X, Huang J, Shi H, et al. Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. J Clin Oncol. 2025. PMID: 41365333. doi:10.1200/JCO-25-02412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。